Trials / Completed
CompletedNCT02756819
International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan
International Multicentre, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Patients With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,945 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to estimate antihypertensive effect of azilsartan medoxomil (Edarbi®) therapy on blood pressure in participants with overweight or obesity in routine clinical practice of hypertension (HTN) treatment in the Russian Federation and in the Republic of Kazakhstan..
Detailed description
The drug being tested in this study is called azilsartan medoxomil (Edarbi®). Azilsartan medoxomil is being tested to treat people who have hypertension. This study looks at the clinic systolic and diastolic blood pressure (SBP, DBP) in obese participants who were prescribed azilsartan medoxomil by physicians. The study enrolled 1945 patients. All participants were asked to take azilsartan medoxomil as prescribed by their physician according to local SmPC. This multi-center trial was conducted in the Russian Federation and the Republic of Kazakhstan. The overall duration of study for observation was approximately 6 months. Participants made multiple visits to the clinics as assigned by each physician according to their routine practice, in every 3 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azilsartan Medoxomil | Azilsartan medoxomil tablets |
Timeline
- Start date
- 2016-07-18
- Primary completion
- 2018-05-08
- Completion
- 2018-05-08
- First posted
- 2016-04-29
- Last updated
- 2019-11-20
- Results posted
- 2019-11-20
Locations
66 sites across 2 countries: Kazakhstan, Russia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02756819. Inclusion in this directory is not an endorsement.